InvestSMART

ImpediMed Limited (ASX:IPD)

ALERT: Price-sensitive ASX Announcement for IPD
Current share price for IPD : $0.006 -0.04 (-86.96%)+
Announcement
Release
30 Oct 2025 8:19AM
Price at Release
$0.046
Full Release
download
Summary
ImpediMed Limited reported a record quarterly revenue of A$3.6 million, with annual recurring revenue increasing to A$14.4 million. The company experienced a net operating cash outflow of A$5.6 million, offset by cash receipts of A$3.4 million, leaving a total cash balance of A$23.0 million by the quarter's end. The launch of the SOZO Pro device, targeted at patients with cardiac implantable devices, marks a significant milestone amidst ongoing efforts to enhance reimbursement coverage, now improved to over 80% in 42 states. ImpediMed continues to focus on financial discipline, including reducing director fees, as it strives towards cash flow breakeven and broader market coverage.
Key Points
  • Revenue for the quarter was A$3.6 million, with annual recurring revenue of A$14.4 million.
  • SOZO Core Business Total Contracted Value was A$4.7 million.
  • Cash receipts from customers amounted to A$3.4 million, while net operating cash outflows totaled A$5.6 million.
  • The total cash balance at the end of the quarter was A$23.0 million.
  • ImpediMed's coverage for reimbursement has improved significantly, with 42 states above 80% coverage.
  • The launch of SOZO Pro, an FDA-cleared device for patients with cardiac implantable devices, has been initiated.
  • Four new system agreements provide access to over 700 hospitals.
  • Net cash from financing activities was A$6.962 million.
  • ImpediMed aims for 100% reimbursement coverage and is focusing on enhancing guidelines and coverage.
  • Director fees were reduced as part of a focus on financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.